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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is the determine whether or not, “oral
steroids are as effective as NSAIDS in relieving patient pain from gout?”
STUDY DESIGN: Review of three English language primary studies, published between 2008
and 2016.
DATA SOURCES: Three randomized controlled trials (RCTs) were found using PubMed and
Embase database. These studies analyzed the effectiveness of steroids in relieving patient pain
from gout.
OUTCOMES MEASURED: The major outcomes measured were improvements in joint
tenderness on palpation, joint erythema, joint swelling, and joint activity measured on a 5-point
Likert scale. (0=no pain, 1=mild pain, 2=moderate pain, 3=severe pain, 4=extreme pain).
Analgesic effectiveness was measured as changes in pain on a 100-mm visual analogue scale.
With 1 being the least pain the patient has ever experiences and 100 being the worst.
RESULTS: All three studies showed comparable efficacy between prednisolone and NSAIDS in
treating gout. The Xu et al study concluded similar results between NSAIDS and Prednisolone in
improving pain, tenderness, and joint activity. Furthermore, the study also stated Prednisolone
may be more effective in reducing inflammation and was better tolerated. The Rainer et al and
Janssen et al study found prednisolone and indomethacin have similar analgesic effectiveness,
and prednisolone is a safe, and effective first line option for gout treatment.
CONCLUSION: The results of all three RCT’s which compared the efficacy between
prednisolone and NSAIDS in the treatment of gout concluded similar results between the two
groups. Therefore, proving steroids as an effective treatment option for patients diagnosed with
gout.
KEY WORDS: Gout, Steroids, and NSAIDS.
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INTRODUCTION
Gout is a metabolic disease associated with abnormal amounts of urates which manifests
as recurrent acute arthritis. 5 The disease will most commonly present in the first metatarsal
phalangeal joint of the great toe also known as “podagra”. 5 Areas such as the feet, ankles, and
knees, are also commonly affected.5 The attacks are characterized by intense pain with swollen,
warm, and tender joints, dusky red skin overlying the joint space, and fever.5 In some cases tophi
can be found on the feet, ears, and hands as a result of accumulation of uric acid crystallization
years after the initial gout attack.5 Purine rich foods are proven to potentiate attacks such as
alcohol, seafood, and thiazide diuretics.5 Patients may be asymptomatic for months or even years
after their first attack. However, if left untreated patients can develop chronic gout. 5 This paper
discusses the results of three randomized control trials to determine if steroids are indeed as
effective as NSAIDS in treating patients diagnosed with gout.
This topic is relevant to both patients and the PA practice because gout is the most
common form of inflammatory arthritis.5 Gout most commonly effects men over the age of 30
years old.5 When gout manifests in women it most commonly appears after the woman is
postmenopausal.5 It is crucial as medical professionals we accurately diagnose and treat gout,
because if left untreated patients can develop chronic gout which can lead to deformation of the
joint spaces mimicking the effects of rheumatoid arthritis. 5 As a result, these patients are at an
increased risk for joint replacements and corrective surgeries.1
Due to the rising frequency and widespread occurrence of gout there is an increased cost
burden associated with the disease.1 For patients who suffer six or more gout flares per year,
direct gout-related health care costs top $12,020.4 Furthermore, according to a 2016 study, gout
hospitalization expenses have increased by 68% from 34,456 to 58,000. 4 There is an increasing
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number of patients who visit their healthcare provider due to gout attacks each year. 4 According
to the “National Ambulatory Survey” between the years of 2008 and 2016, there were 7 million
ambulatory visits due to gout.1 Therefore, there is an overwhelming need in the medical
community to correctly diagnose, treat, and care for patients diagnosed with gout to decrease the
economic burden surrounding the disease.4
Gout is widely understood throughout the medical community as uric acid deposition in
the soft tissue as well as bone and joints.5 However, the amount of uric acid present in the serum
does not depict the severity of the disease.5 Furthermore, the precise relationship between
hyperuricemia and gouty arthritis is still unknown.5 This is because chronic hyperuricemia is
found in those who have never before experienced a gout attack. 5 Instead, medical professionals
rely on arthrocentesis, as the test of choice when diagnosing patients with acute gout.5 The fluid
will show negatively birefringent needle shaped crystals under a light microscopy which
differentiate gout from pseudogout.5
Treatment of gout begins with lifestyle modifications such as a decrease in intake of
purine rich food such as alcohol, seafood, and red meat.5 It is also crucial to consider
medications such as loop and thiazide diuretics which can potentially increase serum uric acid
levels and provoke gout attacks.5 NSAIDS such an Indomethacin are currently used as the drug
of choice in acute gout attacks.5 Colchicine is considered 2 nd line if the patient presents within 36
hours of onset or are refractory to the use of NSAIDS. 5 Steroids are then considered if the
patient is unresponsive to both NSAIDS and Colchicine.5 It is important to treat episodes of
acute gout and chronic gout differently as medications to treat chronic gout can potentiate or
worsen gout symptoms if given during an acute gouty episode. 5 Drugs such as Allopurinol which
reduces uric acid production or Probenecid which promote renal uric acid secretion are available
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to treat patients with recurrent or chronic gout.5 Each treatment listed above has shown to be
beneficial for patients suffering from gout. Treatment is based on patient presentation, timeperiod, and past medical history. In addition, based on the three articles, steroids are proven to be
just as effective as NSAIDS as first line treatment for gouty arthritis.
OBJECTIVE
The objective of this selective EBM review is the determine whether or not, “oral steroids
are as effective as NSAIDS in relieving patient pain from gout?”
METHODS
The population analyzed in this review includes patients diagnosed with gout. One group
was given Prednisone in comparison to the other group which received a trial of NSAIDS. The
outcome studied in these reviews is pain relief, and the patients rated their amount of pain
through a Likert or visual analogue scale. All three studies are randomized controlled trials
which studied the effectiveness of Prednisolone in comparison to NSAIDS.
All three studies were published in peer reviewed English articles. The key words used to
locate the articles included “gout”, “steroids”, and “NSAIDS”, and were searched on the Pubmed
and Embase databases. The articles were chosen based on relevance to the clinical question, and
due to importance to the patient population in order to create a POEM. A POEM stands for
patient-oriented evidence that matters. Inclusion criteria included all randomized controlled
trials published after 2001. Exclusion criteria included patients who used NSAIDS or steroids
24-72 hours prior, had progressed to the chronic gouty arthritis stage, or had been diagnosed with
gastrointestinal disease. The statistics reported in all three studies included confidence interval,
p-value and mean change from baseline. Each of the three studies demographics and
characteristics can be found on Table 1.
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Results: Table of demographics and characteristics of included studies (Table 1)
Study

Type # Pts

Janssens,
2008 (1)

RCT

120

Rainer,
2016 (2)

RCT

416

Lingling RCT
Xu, 2015
(3)

132

Age
(yrs)
All ages

Inclusion
Criteria
Pts with
monoarticular
gout
confirmed by
arthrocentesis.
Pts were
required to
give consent.

Exclusion
Criteria
Pts with
comorbidities
such as renal
failure or heart
attack. Pts with
history of GI
disease. Pts
were not
allowed to have
NSAIDs or
other pain meds
24 hours prior.
Pts aged Pts who
Pts were not
18 years presented to
allowed to
or older the ER within receive steroids
3 days of
or NSAIDs
symptom
within 24 hours.
onset. Pts
Pts with hx of
were
comorbidities,
evaluated by a suspected septic
physician to
arthritis or
be diagnosed history of
with gout.
bleeding
disorders.
Pts aged Pts who
Pts were
18 years presented
excluded if they
and
with gout
had chronic
older
attacks within gouty arthritis,
72 hours of
clinical
screening.
suspicion of
The degree of joint disease,
pain on the
comorbidities,
Likert scale
GI issues,
was at least
NSAIDS or
moderate.
steroids within
72 hours.

W/D

Interventions

1

Prednisolone

40

Prednisolone

19

Prednisolone

4
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OUTCOMES MEASURED
All three studies measured the outcome of pain relief through either a 5-point Likert scale
or visual analog scale. The Xu et al study primarily focused on the reduction of pain as
experienced by the patient.7 The degree of joint pain was represented by a 5-point Likert scale
(0=no pain, 2=moderate pain, 3=severe pain, 4=extreme pain).7 The number was then recorded
by the patient on day 1 before the start of treatment and on day 2 and 4 approximately 4 hours
after the dose of drug was administered.7 The physician also measured the patient’s overall
response to treatment on a 5- point Likert scale (0=very good, 1=good, 2=fair, 3=poor, 4=very
poor) at day 4 at the end of the study.7 Although the study also analyzed joint tenderness to
palpation, joint erythema, joint swelling, and joint activity, for the purpose of study only pain
scores were analyzed.7 The remaining two studies measured analgesic effectiveness as changes
in pain on a visual analogue scale with 1 being the least amount of pain the patient has ever
experienced to 100 being the worst.
RESULTS
All three studies included in this paper are randomized control trials studying the
effectiveness of Prednisolone in comparison to NSAIDS in the treatment of gout. Although each
study implemented different participant age requirements, all patients were included if they were
diagnosed with acute gouty arthritis. All studies presented data in continuous format and no
dichotomous data was converted. Changes in mean score, confidence interval, and p-value with a
significance of  0.05 was analyzed.
In the Xu et al study, 132 inpatients aged 18 or older with acute gouty arthritis within 72
hours of onset were randomly assigned to trial treatments.7 These patients were diagnosed with
gout according to the clinical criteria of the 1977 American College of Rheumatology
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classification.7 The participants were chosen based on the inclusion and exclusion criteria listed
in Table 1. The patients were randomly assigned using computer-generated tables and prepared
by an independent party.7 The participants received either Prednisolone 35 mg qd, Etoricoxib
120 mg qd, or Indomethacin 50 mg tid. 7 The patients were only studied for 4 days due to the
self-limiting nature of acute gouty arthritis.7 The participants pain levels were measured using a
5-point Likert scale and the same physician observed and studied each patient throughout the 4
days.7 Of the 132 patients who were randomized, 113 participants were ultimately analyzed. Of
the 113 studied, 33 were given Prednisolone, 44 were given Etoricoxib, and 36 were given
Indomethacin.7 Adverse effects noted during the trial mainly included gastric or abdominal pain,
dizziness, edema, fatigue, drowsiness, and dry mouth.7
The results demonstrate both Indomethacin and Prednisolone significantly decrease the
severity and pain of acute gouty arthritis. The mean difference between the two groups is 0.11
with a p value of 0.416.7 The treatment effect is small. This is because the reduction in pain
when comparing Prednisolone to Indomethacin is 0.11. The confidence interval is wide at 95% (0.16 to 0.39). 7 This is due to the small sample size.7 The p-value is 0.415.7 Therefore, because
the p > 0.005 there is no significant difference between the groups. The efficacy of Prednisone in
reducing pain was comparable to Indomethacin after 4 days. Furthermore, there is no significant
difference between the groups and Prednisolone can be used just as effectively to treat gout.
Results: Indomethacin vs Prednisolone (Table 2)
Group

Value Measured

LS Mean Difference

Confidence Interval

P Value

Prednisolone
vs
Indomethacin

Pain

0.11 (.0138)

-0.16 to 0.39

0.415
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In the Rainer et al double-blind randomized trial, 416 patients aged 18 years or older with
a clinical diagnosis of acute gout were enrolled in the study. 3 Of the 416 enrolled, 376 completed
the study. 3 The patients were chosen based on the inclusion and exclusion criteria listed in table
1. Patients were randomly assigned using a 1:1 ratio to receive either Indomethacin or
Prednisolone for 5 days.3 The physicians and patients were unaware of which drug they were to
receive. In the Indomethacin group (n=208), patients initially received 50mg (two 25mg tablets)
of oral Indomethacin 3 times daily. 3 Patients were also given 6 tablets of oral placebo
Prednisolone to take once daily for 2 days. 3 This was followed by 25 mg of Indomethacin 3
times a day and the placebo Prednisolone to take once per day for 3 days. 3 In the Prednisolone
group (n=208), patients initially took 30 mg (three 10mg tablets) of oral Prednisolone once a
day, and 2 tablets of placebo Indomethacin 3 times a day for 2 days. 3 This was followed by
30mg (three 10 mg tablets) of Prednisolone once a day and 1 tablet of placebo Indomethacin 3
times a day for 3 days.3 Patients were required to take the first dose in the presence of one of the
investigators and all patients were given the analgesic Acetaminophen to use as needed. 3 The
results were measured using a 100mm visual analogue scale.3
When comparing the effectiveness of Indomethacin to Prednisolone in this study, there
was a small difference between the two groups. While measuring decrease in pain scores on days
1-14 while the patient was a rest, demonstrated a reduction of 1.67 mm for Indomethacin and
1.52 mm for Prednisolone.3 As a result, the difference in mean pain score between the two
groups is 0.15 mm.3 Furthermore, the number of patients which demonstrated a significant
change in their pain score was calculated.3 Among the patients who received Indomethacin, 111
patients illustrated a significant change, and in the Prednisolone group 101 patients demonstrated
a change in pain score.3 Therefore, the average difference between the two
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groups are 10 (4.8%).3 Ultimately, when analyzing the small mean difference and p-value of
0.92, which is clinically insignificant, indicates Prednisolone can be used as effectively as
NSAIDS in the treatment of gout.
Results: Indomethacin vs Prednisolone (Table 3)
Day 1-14

Indomethacin

Prednisolone

At Rest

N=208

N=208

1.67 (1.36 to 1.98)

N=111

Difference

P Value

1.52 (1.25 to 1.79)

0.15

0.92

N=101

10

Mean Decrease in
Pain Score (95% CI)
Patients with
significant change in
Pain Score

In the Janssens et al study, 120 patients were randomly assigned to trial treatments. 2
Between the months of March 24, 2004 and July 14th, 2006, family doctors were asked to send
all patients with monoarthritis to the trial center. 2 These patients were sent even if gout was not
the primary diagnosis, to minimize the risk of missing potential study participants. 2 Patients were
then assessed in the trial center for inclusion eligibility within day 1 after they visited their
family doctor.2 Patients were separated randomly into two groups by computer generated
randomization, and 60 patients were in each group. 2 Both the patients and the physicians were
unware which group received Naproxen or Prednisolone.2 The first group received one 35 mg
tablet of Prednisolone, and the other group received 500 mg of Naproxen which was taken twice
a day. 2 The trial period lasted for 5 days.2 The results were measured on a 100mm visual
analogue scale.2 The adverse effects recorded were similar to the Rainer study, and resolved
within 3 weeks.2
This study further indicated the similar efficacy of Prednisolone in comparison to
NSAIDS.2 Pain score was measured at baseline and at 90 hours. Pain score at baseline for
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Prednisolone was 61.5 mm, and 58.9 mm for Naproxen.2 After 90 hours, pain score for
Prednisolone was 16.8 mm, and 12.9 mm for Naproxen.2 Therefore, patients who took
Prednisolone had a pain decrease of 44.7mm, and those who took Naproxen had a decrease of
46.0 mm.2 This equals a 1.3 mm overall difference between the two medications. 2 The
confidence interval is (-9.8 to 7.1). 2 The confidence interval is wide due to small sample size,
however the small change in mean from baseline proves there is no significant difference
between the groups.2 Adverse side effects included nausea, dizziness, and sleepiness. No major
side effects were reported.2
Results: Naproxen vs Prednisolone (Table 4)
Prednisolone (n=59)

Naproxen (n=59)

Baseline: 61.5

Baseline: 58.9

After 90 hr: 16.8

After 90 hr: 12.9

Score Reduction: 44.7

Score Reduction: 46.0

DISCUSSION
Due to the statistics presented above it is evident Prednisolone is as effective as NSAIDS
in the treatment of acute gout. All three studies found a similar reduction in pain score between
the steroid and NSAID group. Furthermore, the p-values calculated in the studies were clinically
insignificant indicating both drugs can be used interchangeably. The Xu et al RCT claimed
efficacy was comparable among Prednisolone, Etoricoxib, and Indomethacin in treating acute
gout.7 However, Prednisolone might be more effective in reducing inflammation and was better
tolerated.7 Furthermore, the Xu et al study found that patients experienced more total adverse
events with Indomethacin compared to Prednisolone. 7 The Rainer et al study claimed
Prednisolone is a safe, effective first line treatment for acute gout. 3 Per current medication
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guidelines, NSAIDS are the first line treatment option for patients presenting with acute gout.
However, due to the data presented above it is reasonable to consider Prednisolone as an
alternative first line treatment to NSIADs in treating gouty arthritis.
After reviewing the different methods and study designs it is apparent there were some
limitations. Firstly, it is important to note the definitive diagnoses for acute gout is arthrocentesis
where the fluid is analyzed to determine the diagnosis. 5 However, only the Janssens et al study
diagnosed patient gout with arthrocentesis. The other two studies only used clinical judgment to
make a diagnosis. Therefore, it is uncertain that all patients in the studies without arthrocentesis
had gout. This diagnostic uncertainty could have resulted in inaccurate data. Secondly, the
sample sizes in each study were small. The Janssens et al and Xu et al both studied around 130
patients, and the Rainer et al, analyzed around 400. Therefore, it is difficult to make large scale
predictions on the data due to the small amount of the population represented in the studies.
Thirdly, the time-period to which the patients were studied was relatively short. The Rainer et al
RCT was the only study to analyze patients for over a week. The presentation of acute gout is
limited and may only last for hours to a few short days. 5 Therefore, due to the limited nature of
acute gout it is difficult to study it for a significant amount of time.
Prednisolone is a good and convenient treatment option due to its affordability, and
accessibility.8 It is also crucial to provide patient education about the medication prescribed, and
encourage each patient to finish their prescription to avoid relapses and unwanted medical costs.1
Furthermore, most patients will be familiar with steroid medications and will feel comfortable
taking their prescription.8 However, physicians do have their hesitations about steroids due to
cushing’s syndrome, diabetes mellitus, hypertension, and osteoporosis. 7 However, side effects
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associated with NSAID use include gastrointestinal stomach pain, bleeding and peptic ulcers. 7
Furthermore, all medications will present potential risks and benefits.
CONCLUSION
The results of all three RCT indicate Prednisolone is just as effective as NSAIDS in the
treatment of patients diagnosed with acute gout. Due to the increasing number of patients
diagnosed with gout each year, it is important to consider different treatment options other than
NSIADS to treat patient symptoms.1 It is also crucial to provide patient education about the
medication prescribed, and encourage each patient to finish their prescription to avoid relapses
and unwanted medical costs.1 If patients are not taking their medications as prescribed it is
impossible to determine the efficacy of the medication. Furthermore, it is important all future
studies consider and ensure patient compliance. It is imperative studies use arthrocentesis as a
diagnosis requirement, as well as implement larger sample sizes to study different medication
options. This would improve accuracy and credibility of each study. Lastly, it is important
scientists and physicians continue to expand on treatment options for all patients, to successfully
care and treat each individual patient diagnosed with acute gouty arthritis.
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